UBS Group
GDTC icon

UBS Group’s CytoMed Therapeutics GDTC Stock Holding History

UBS Group’s Portfolio GDTC Stock Details GDTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.18K Buy
6,182
+5,117
+480% +$5.39K ﹤0.01% 8709
2025
Q4 		$1.42K Sell
1,065
-12,224
-92% -$23.7K ﹤0.01% 9591
2025
Q3 		$26.4K Sell
13,289
-4,292
-24% -$8.42K ﹤0.01% 7981
2025
Q2 		$39.6K Buy
17,581
+3,134
+22% +$7.14K ﹤0.01% 7962
2025
Q1 		$31.5K Buy
14,447
+4,349
+43% +$11.5K ﹤0.01% 7908
2024
Q4 		$34.3K Buy
10,098
+10,037
+16,454% +$24.1K ﹤0.01% 7526
2024
Q3 		$96 Buy
+61
New +$106 ﹤0.01% 9162
2024
Q1 		– Sell
-3,500
Closed -$17.1K – 9569
2023
Q4 		$17.1K Buy
3,500
+3,023
+634% +$11.4K ﹤0.01% 7198
2023
Q3 		$1.67K Buy
477
+423
+783% +$1.6K ﹤0.01% 7860
2023
Q2 		$165 Buy
+54
New +$168 ﹤0.01% 8432

Other funds holding GDTC

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's GDTC Position: Q1 2026 in Review

UBS Group increased its CytoMed Therapeutics (GDTC) stake by 480% in Q1 2026, buying an estimated $5.39K and bringing the position to 6,182 shares worth $6.18K. The position accounts for ﹤0.01% of the portfolio, ranked #8709.

UBS Group first reported a position in GDTC in Q2 2023 and has held it in 10 quarters since. The position peaked at $39.6K in Q2 2025. 3 funds tracked by Wall St. Rank hold GDTC as of Q1 2026.

  • UBS Group held 6,182 shares of CytoMed Therapeutics worth $6.18K as of Q1 2026.
  • UBS Group bought 5,117 CytoMed Therapeutics shares in Q1 2026, an estimated $5.39K.
  • CytoMed Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8709 holding.
  • UBS Group first reported a position in CytoMed Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • UBS Group's CytoMed Therapeutics position peaked at $39.6K in Q2 2025.
  • 3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.